2018
DOI: 10.2174/9781681082134118010005
|View full text |Cite
|
Sign up to set email alerts
|

Clinical Trials of Curcumin, Camptothecin, Astaxanthin and Biochanin

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…Over the past half-century, a high amount of distinct clinical trials have been accomplished to address curcumin's efficacy, safety, and pharmacokinetics (Gupta et al, 2013;Subramani et al, 2018). Curcumin has been administered in several formulations, such as capsules, tablets, powder nanoparticles, liposomal encapsulation, and emulsions, with dose-escalating studies revealing that curcumin is safe at doses as high as 12 g/day for 3 months.…”
Section: Concluding Remarks and Perspectivesmentioning
confidence: 99%
“…Over the past half-century, a high amount of distinct clinical trials have been accomplished to address curcumin's efficacy, safety, and pharmacokinetics (Gupta et al, 2013;Subramani et al, 2018). Curcumin has been administered in several formulations, such as capsules, tablets, powder nanoparticles, liposomal encapsulation, and emulsions, with dose-escalating studies revealing that curcumin is safe at doses as high as 12 g/day for 3 months.…”
Section: Concluding Remarks and Perspectivesmentioning
confidence: 99%
“…Curcumin is still utilized as a cooking ingredient today, but modern technology has made it possible to use it in a range of food-and healthrelated applications. Curcumin's efficacy, safety, and pharmacokinetics have all been examined extensively in clinical studies over the last 50 years (Gupta et al, 2013;Subramani et al, 2018). The development of innovative nanomedicine formulations to increase curcumin targeting, pharmacokinetics, efficacy, and cellular uptake has been prompted by a significant therapeutic limitation (Salehi et al, 2020a;Salehi et al, 2020b).…”
Section: Discussionmentioning
confidence: 99%